Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

Basit Öğe Kaydı
dc.authoridKarabay, Oguz/0000-0003-1514-1685;
dc.authorwosidKöksal, Aydın Şeref/AAM-5452-2020
dc.authorwosidKaymakoglu, Sabahattin/AAT-2362-2020
dc.authorwosidGumus, Mahmut/C-7135-2008
dc.authorwosidTabak, Ömer Fehmi/A-1192-2018
dc.authorwosidOrmeci, Necati/K-1194-2018
dc.authorwosidKarabay, Oguz/HHN-5893-2022
dc.authorwosidKöksal, Aydın Şeref/AAT-4766-2020
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorDemir, Ahmet Muzaffer
dc.contributor.authorGumus, Mahmut
dc.contributor.authorKarabay, Oguz
dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorKoksal, Aydin Seref
dc.contributor.authorKoksal, Iftihar
dc.date.accessioned2024-06-12T11:03:09Z
dc.date.available2024-06-12T11:03:09Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThis consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.en_US
dc.identifier.doi10.5152/tjg.2018.18263
dc.identifier.endpage269en_US
dc.identifier.issn1300-4948
dc.identifier.issn2148-5607
dc.identifier.issue3en_US
dc.identifier.pmid29755010en_US
dc.identifier.scopus2-s2.0-85055830494en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage259en_US
dc.identifier.trdizinid289048en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2018.18263
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/289048
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21551
dc.identifier.volume29en_US
dc.identifier.wosWOS:000440300700002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal Of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis Ben_US
dc.subjectImmunosuppressive Therapyen_US
dc.subjectReactivation Risken_US
dc.subjectAntiviral Prophylaxisen_US
dc.subjectStem-Cell Transplantationen_US
dc.subjectVirus Hbv Reactivationen_US
dc.subjectCytotoxic Chemotherapyen_US
dc.subjectSurface-Antigenen_US
dc.subjectCancer-Patientsen_US
dc.subjectPreventionen_US
dc.subjectManagementen_US
dc.subjectLymphomaen_US
dc.subjectIdentificationen_US
dc.subjectProphylaxisen_US
dc.titleImmunosuppressive therapy and the risk of hepatitis B reactivation: Consensus reporten_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu